1. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial JAMA. 1998;280(17):1485-1489. doi:10.1001/jama.280.17.1485 Figure 1.—Randomization of patients into radiotherapy groupand observation group. Figure Legend:

2. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial JAMA. 1998;280(17):1485-1489. doi:10.1001/jama.280.17.1485 Figure 2.—The length of time to recurrence of tumor anywherein the brain was significantly (P<.001) longerin patients in the radiotherapy group (white squares) than in the observationgroup (black circles), median 220 weeks vs 26 weeks (relative risk of anybrain recurrence, 4.94; 95% confidence interval, 2.36-10.35). Tick marks indicatepatients (living or dead) in whom brain recurrences did not develop. Figure Legend:

3. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial JAMA. 1998;280(17):1485-1489. doi:10.1001/jama.280.17.1485 Figure 3.—The length of time from treatment to the developmentof recurrence of the original brain metastases was significantly (P<.001) longer in patients in the radiation group (white squares)than in the observation group (black circles), more than 50 weeks vs median27 weeks (relative risk of original recurrence, 6.03; 95% confidence interval,2.48-14.65). Recurrence of the original brain metastasis was defined as thereappearance of a metastasis in the exact site in the brain as the first brainmetastasis. Tick marks indicate patients (living or dead) who did not developrecurrences of the original metastasis. Figure Legend:

4. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial JAMA. 1998;280(17):1485-1489. doi:10.1001/jama.280.17.1485 Figure 4.—The length of time to recurrence of distant brainmetastasis was significantly (P=.04) longer in the49 patients in the radiation group (220 weeks) (white squares) than in the46 patients in the observation group (53 weeks) (black circles) (relativerisk of distant brain recurrence, 2.77; 95% confidence interval, 1.16-6.59).Recurrence of distant brain metastasis was defined as the appearance of anew metastasis at a site in the brain different from the site of the originalbrain metastasis. Tick marks indicate patients (living or dead) who did notdevelop distant brain metastases. Figure Legend:

5. Date of download: 9/18/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial JAMA. 1998;280(17):1485-1489. doi:10.1001/jama.280.17.1485 Figure 5.—When only deaths due to neurologic causes were usedas endpoints and data on patients who died from nonneurologic causes werecensored, there was a significant (P=.03) differencebetween the 2 treatment groups. The radiation group (white squares) had amedian survival of more than 115 weeks, and the observation group (black circles)had a median survival of 81 weeks (relative risk of death from neurologiccauses, 2.62; 95% confidence interval, 1.03-6.64). Length of survival wasmeasured from the beginning of treatment for the original brain metastasis.Tick marks indicate patients who did not die of neurologic causes or the lastfollow-up evaluation in living patients. Figure Legend: